1KJ.F 10X GENOMICS DL -00001
- Market cap
- EUR 7.39B
- P/E
- -
- P/B
- 9.89x
- ROE
- -8.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1KJ.F undervalued?
Graham numberThe Graham number of 10X GENOMICS DL -00001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
10X GENOMICS DL -00001 fundamental analysis
No fundamental analysis for 10X GENOMICS DL -00001 yet.
10X GENOMICS DL -00001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 10X GENOMICS DL -00001
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale sing…
Full company profile10X GENOMICS DL -00001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
10X GENOMICS DL -00001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 516M | 619M | 611M | 643M | 603M |
| Gross Profit | 396M | 409M | 414M | 444M | 442M |
| Operating Income | -168M | -204M | -195M | -111M | -74.7M |
| EBITDA | -128M | -205M | -134M | 3.91M | -25.3M |
| Net Income | -166M | -255M | -183M | -43.5M | -67.8M |
| EPS | -1.44 | -2.14 | -1.49 | -0.34 | -0.52 |
| Balance Sheet | |||||
| Total Assets | 1.03B | 965M | 919M | 1.04B | 1.06B |
| Total Liabilities | 223M | 224M | 209M | 245M | 225M |
| Shareholders' Equity | 806M | 741M | 710M | 796M | 838M |
| Cash & Short-term Investments | 220M | 359M | 344M | 474M | 526M |
| Cash Flow | |||||
| Operating Cash Flow | -33.6M | -15.2M | 6.66M | 136M | 78.6M |
| Capital Expenditure | 132M | 49.5M | 13.4M | 5.94M | 5.54M |
| Free Cash Flow | -165M | -64.7M | -6.73M | 130M | 73.0M |
| Ratios | |||||
| ROE | -20.6% | -34.4% | -25.7% | -5.5% | -8.1% |
| ROA | -16.1% | -26.4% | -19.9% | -4.2% | -6.4% |
| Net Profit Margin | -32.1% | -41.2% | -29.9% | -6.8% | -11.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
10X GENOMICS DL -00001 dividends
10X GENOMICS DL -00001 has not paid dividends in the last 4 fiscal years.
Who owns 10X GENOMICS DL -00001
- Insiders 1.43%
- Institutions 98.57%
- Public & others 0.00%
- Shares outstanding 121M
- Free float 119M
10X GENOMICS DL -00001 company profile
- Company name
- 10X GENOMICS DL -00001
- Ticker
- 1KJ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 1,178
- Fiscal year end
- December
- Address
- 6230 Stoneridge Mall Road, Pleasanton, CA, United States, 94588-3260
- Phone
- 925 401 7300
- Website
- 10xgenomics.com
About 10X GENOMICS DL -00001
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
10X GENOMICS DL -00001 management
8- Dr. Serge Saxonov Ph.D.Co-Founder, CEO & Director · born 1977
- Dr. Benjamin J. Hindson Ph.D.Co-Founder, President, Chief Scientific Officer & Director · born 1975
- Mr. Adam S. TaichCFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · born 1975
- Mr. Jim GoodrichChief of Global Operations
- Mr. Michael Schnall-Levin Ph.D.Founding Scientist & CTO
- Ms. Cassie CorneauManager of Investor Relations & Strategic Finance
- Ms. Mennah MoustafaChief Commercial Officer
- Mr. Jens DurruthyAssociate Director of Product Management